ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.

ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.
复制标题

ITPA 基因分型不能预测 AZA 治疗的炎症性肠病患者副作用的发生。

DOI：
--
复制
发表时间：
2005
期刊：
Gut
影响因子：
24.5
通讯作者：
C. J. V. D. Woude
C. J. V. D. Woude
中科院分区：
医学1区
文献类型：
--
作者：
J. V. Dieren;A. J. V. Vuuren;Johannes G. Kusters;E. Nieuwenhuis;E. Kuipers;C. J. V. D. Woude

文献摘要

被引文献

相似文献

We read with interest the letter by Colombel et al on the non-predictive value of ITPA genotyping for the development of myelosuppression after azathioprine (AZA) treatment ( Gut 2005; 54 :565). The level of thiopurine methyltransferase (TPMT) activity is determined by a common genetic polymorphism.1 It was shown that low TPMT activity is linked to a higher relative risk of development of myelosuppression after AZA treatment.2 Testing for TPMT genotype before the start of AZA treatment is of limited clinical value as myelosuppression resulting from TPMT mutations occurs in less then one third of patients with myelosuppression.3 Polymorphisms in genes encoding inosine triphosphate …